The prevalence of BRAF gene mutations among Egyptian patients with Papillary Thyroid Carcinoma /
Sara Mohamed Tawfic Elkhateeb
The prevalence of BRAF gene mutations among Egyptian patients with Papillary Thyroid Carcinoma / شيوع طفرة البى راف فى المرضى المصريين المصابين بسرطان الغدة الدرقية الحليمى Sara Mohamed Tawfic Elkhateeb ; Supervised Ahmed Eltaweel , Sherif Elrafaei , Dina Ahmed Mehaney - Cairo : Sara Mohamed Tawfic Elkhateeb , 2013 - 92 P. : charts , facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Background: The activating point mutation v-Raf murine sarcoma viral oncogene homology B1 (BRAFV600E), is the most common and specific genetic alteration in papillary thyroid carcinoma (PTC) with a prevalence of 29-83% the mutation causes a change in amino acid at position 600 from valine to glutamic acid in the BRAF protein kinase, resulting in aberrant activation of the mitogen- activated protein MAP kinase signaling pathway
BRAFV600E Mutation Papillary thyroid carcinoma
The prevalence of BRAF gene mutations among Egyptian patients with Papillary Thyroid Carcinoma / شيوع طفرة البى راف فى المرضى المصريين المصابين بسرطان الغدة الدرقية الحليمى Sara Mohamed Tawfic Elkhateeb ; Supervised Ahmed Eltaweel , Sherif Elrafaei , Dina Ahmed Mehaney - Cairo : Sara Mohamed Tawfic Elkhateeb , 2013 - 92 P. : charts , facsimiles ; 25cm
Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology
Background: The activating point mutation v-Raf murine sarcoma viral oncogene homology B1 (BRAFV600E), is the most common and specific genetic alteration in papillary thyroid carcinoma (PTC) with a prevalence of 29-83% the mutation causes a change in amino acid at position 600 from valine to glutamic acid in the BRAF protein kinase, resulting in aberrant activation of the mitogen- activated protein MAP kinase signaling pathway
BRAFV600E Mutation Papillary thyroid carcinoma